• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169941 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  2 p5 q! w( Y; ?! o
: E$ U. O$ I# T9 o- N2 h$ f

, M5 i- h, x0 s7 NSub-category:
+ p& t9 x6 R' h' t/ _6 D5 f$ nMolecular Targets + j# B& u5 L6 n, c

5 l6 K. z0 M: [8 L
' `0 }& Y9 b# B& y# ~+ N, zCategory:  ?3 e* B6 q3 h& n5 N; ~
Tumor Biology
' z& i- j% \% p$ l3 n) c1 p' n& X( Q& Z& M( s

" i4 c$ O- G" V/ iMeeting:
6 A$ a! F& j$ y, J$ @5 A6 Y2011 ASCO Annual Meeting
# y6 a  E. H- d2 I7 r7 o; L7 u% ~6 T/ i
+ C6 |( i& Y( z6 _. a
/ l6 V$ g9 U* {% R$ OSession Type and Session Title:  p$ s0 u2 P, x2 z& _* B' W0 o
Poster Discussion Session, Tumor Biology , D& X( N' S$ i" b. d, O

# E% Y) D* d) t7 u) P6 Y5 L
1 z8 O% W1 ?% H  QAbstract No:
& P7 H7 }1 o8 y! ~" Z10517 * e3 T, j, t. O  O7 ~" c' s

2 L' V# o' D$ E. R, L
* L/ t2 A9 m$ D8 T" ]8 q( U* ~Citation:
, R: |) z; k0 {$ n1 a% kJ Clin Oncol 29: 2011 (suppl; abstr 10517)
# ]9 x6 u3 |# B  k
2 L* K. o9 a' D7 ]7 @- w2 R6 ~  V/ m0 D  X
Author(s):: D9 A- P& `3 {
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China * Q* O/ I1 m# w; ?( |

% d* R8 c8 g4 Z
  [. X" Y! U$ a) d5 }( Y" x: @  m, I+ E* e/ X& _8 a
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings." e  `8 ~, @* S; s3 C; X5 K9 {

9 g# q% u  \+ O+ h5 a4 o+ B% u8 ]1 {Abstract Disclosures
! ?- s  ~/ }, a& Q1 L9 M# j* A& h4 e# L
& z% s+ P& S# Y' MAbstract:: Y' p% F7 d* l) ?
( b2 A7 \& I4 X( v$ V* Y4 O

* [/ F" q" n! ^. |) G. OBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. }) k* s8 p" M6 T1 ]6 v; l( o0 A6 q
& e4 K9 O' t, z
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
3 n5 B  e& w% I! I4 g" S2 V没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
; g. w7 j. V0 ~( ^  g
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 1 F; p# o: W7 y0 v
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。* A' _$ \: f- u: M- A
ALK一个指标医院要900多 ...
. X/ {7 }4 m0 W; R& F( a# G
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?. g9 ?4 N& y9 h/ z4 {5 W2 |" v

' k0 T/ o4 R' O) y0 `3 ?& j现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表